Completed PHASE1 INTERVENTIONAL 1-arm NCT01989949

Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women (BAL)

Phase 1, Open-Label, Safety and Pharmacokinetic Study to Assess Bronchopulmonary Disposition of Intravenous TP-434 in Healthy Men and Women

Sponsor: Department of Health and Human Services

Conditions Normal Drug Tolerance

Interventions TP-434 (Eravacycline) reconstituted and administered via an IV infusion

Updated 8 times since 2017 Last updated: Dec 16, 2021 Started: Nov 30, 2012 Primary completion: Jan 31, 2013 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Normal Drug Tolerance, this trial is completed. The trial is conducted by Department of Health and Human Services and has accumulated 8 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jan 2022 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Department of Health and Human Services
Tetraphase Pharmaceuticals, Inc

Data source: La Jolla Pharmaceutical Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hartford, United States